ICON Public Limited (NASDAQ:ICLR) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of ICON Public Limited (NASDAQ:ICLR) have received an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $310.45.

Several brokerages have issued reports on ICLR. Redburn Atlantic started coverage on ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price objective for the company. The Goldman Sachs Group reduced their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday. Truist Financial dropped their target price on shares of ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Finally, TD Cowen dropped their price objective on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research report on Friday.

ICON Public Stock Down 0.6 %

Shares of NASDAQ ICLR opened at $220.47 on Friday. The business has a fifty day moving average of $297.75 and a two-hundred day moving average of $310.26. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. ICON Public has a 52-week low of $220.01 and a 52-week high of $347.72. The stock has a market cap of $18.19 billion, a PE ratio of 25.70, a PEG ratio of 1.35 and a beta of 1.22.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. ICON Public’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.10 earnings per share. As a group, equities research analysts expect that ICON Public will post 14.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ICON Public

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Liontrust Investment Partners LLP raised its position in shares of ICON Public by 19.5% in the 2nd quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock valued at $37,531,000 after acquiring an additional 19,546 shares during the period. Kornitzer Capital Management Inc. KS raised its holdings in ICON Public by 15.9% in the second quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock worth $30,016,000 after purchasing an additional 13,163 shares during the period. Sara Bay Financial bought a new position in shares of ICON Public during the third quarter worth $1,143,000. SkyView Investment Advisors LLC acquired a new position in shares of ICON Public in the 1st quarter valued at $1,021,000. Finally, Crestwood Advisors Group LLC bought a new stake in shares of ICON Public in the 2nd quarter valued at $288,000. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.